Skip to content
STAT: psychedelics· Elaine Chen·PickAI score83

Definium says LSD therapy DT120 helped major depression in first Phase 3 trial

STAT+: Definium LSD therapy helped patients with major depression in late-stage trial

AI summary

Definium Therapeutics said on Monday that its LSD therapy DT120 significantly helped patients with major depression in its first trial. Six weeks after a single dose。

Why it matters

The topline gives the first Phase 3 readout for an LSD-based depression treatment, so the size of the placebo gap and the waning at 12 weeks are the numbers that will shape the next regulatory step.

Key facts

Kind of item
Trial results
Compound
LSD
Condition
Depression
Trial phase
Phase 3
Source
STAT: psychedelics (statnews.com)
Published
How this summary was made

The summary and the “Why it matters” note were written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: STAT: psychedelics · statnews.com

Connected to

Kind of item
Trial results
Compound
LSD
Condition
Depression

Other recent items on these topics